Cancer drugs make up about a third of AstraZeneca’s revenue, and the company has added seven oncology treatments since 2014, according to Bloomberg. Based on its pacing, it could double its portfolio by 2030 — a big feat that would surpass the market’s current leaders, Bristol Myers Squibb and Roche.
“We have the opportunity to be the No.1 oncology player,” Dave Fredrickson, executive vice president of oncology business at AstraZeneca, told Bloomberg. “The strategy’s working that we have in place.”
Cancer treatments are the most lucrative market for pharmaceutical companies, with sales of $143 billion in 2019, according to McKinsey.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
